Compare BLCO & PRGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLCO | PRGO |
|---|---|---|
| Founded | 1853 | 1887 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 1.8B |
| IPO Year | 2022 | 1991 |
| Metric | BLCO | PRGO |
|---|---|---|
| Price | $16.99 | $13.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 4 |
| Target Price | $17.31 | ★ $22.50 |
| AVG Volume (30 Days) | 399.7K | ★ 3.7M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 8.83% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,976,000,000.00 | $4,281,800,000.00 |
| Revenue This Year | $8.08 | N/A |
| Revenue Next Year | $5.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.23 | N/A |
| 52 Week Low | $10.45 | $12.17 |
| 52 Week High | $18.99 | $30.93 |
| Indicator | BLCO | PRGO |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 33.32 |
| Support Level | $16.39 | $12.93 |
| Resistance Level | $17.41 | $13.63 |
| Average True Range (ATR) | 0.46 | 0.43 |
| MACD | 0.06 | 0.29 |
| Stochastic Oscillator | 72.71 | 44.25 |
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.